Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand to Report First Quarter 2019 Results on May 2nd
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Ligand to Participate in Four Upcoming Investor Conferences
Ligand Provides Highlights from Today’s Analyst Day Event
Ligand Sells Promacta Assets and Royalty for $827 Million
Reminder: Ligand to Host Analyst Day on March 12th in New York City
Ligand Reports Fourth Quarter and Full Year 2018 Financial Results
Ligand Announces OmniAb® Partnership with Genagon Therapeutics
Ligand Announces Investment in Dianomi Therapeutics
Ligand Partner Seelos Therapeutics Becomes a Public Company
Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th
Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance
Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
